中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

聚乙二醇化干扰素-α 2a治疗慢性丙型肝炎并发甲状腺疾病患者的临床疗效观察

作者：马会乐郭章林邱国华路遥韩俊梅李明慧谢尧

单位：1.晋城市第三人民医院内一科晋城 048026 2.首都医科大学附属北京地坛医院内四科北京 100015

关键词：肝炎丙型慢性甲状腺疾病聚乙二醇类干扰素α

分类号：

出版年,卷(期):页码：2013,5(2):39-42

摘要：

摘要：目的观察聚乙二醇化干扰素（Peg-IFN）-α 2a治疗慢性丙型肝炎（CHC）并发甲状腺疾病患者的效果及安全性。方法选择CHC患者56例，均未并发肝硬化，其中28例并发甲状腺疾病为A组，28例无甲状腺疾病为B组，均接受Peg-IFN-α 2a联合利巴韦林治疗，分别于治疗4周、12周、48周及随访24周时评价疗效，并观察两组患者肝功能及甲状腺功能变化情况。Peg-IFN-α 2a治疗中，A组给予抗甲状腺药物或左甲状腺素片替代治疗，B组出现甲状腺功能异常时给予严密监测，必要治疗甲状腺疾病，均完成抗病毒治疗。结果治疗48周，A组病毒学应答率为92.8%，B组为96.4%；A组持续病毒应答率为89.2%，B组为92.8%，两组均具有良好疗效，差异无统计学意义（P均＞ 0.05）。两组患者肝功能均随抗丙型肝炎病毒治疗而好转。结论 Peg-IFN-α 2a联合利巴韦林治疗CHC并发甲状腺疾病是安全、有效的。

Abstract: Objective To observe the effect and safety of pegylated interferon for chronic hepatitis C (CHC) patients with thyroid dysfunction. Methods Total of 56 patients with CHC without liver cirrhosis were divided into complication thyroid disease of group A (28 cases) and without thyroid disease of group B (28 cases). Both groups were treated with Peg-IFN-α 2a and ribavirin. The evaluation of efficacy, liver function and thyroid function were analyzed at 4th week, 12th week, 48th week and the 24th week of follow-up, respectively. Results At 48th week, the virologic response rate of group A was 92.8% and of 96.4% for group B, the sustained viral response rates of group A was 89.2% and 92.8% for group B. There were no significant difference between two groups (P ＞ 0.05). Liver function of both groups improved after anti-HCV therapy. Conclusions Peg-IFN-α 2a combined with ribavirin in treatment of patients with CHC complicated with thyroid disease was safe and effective.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】